FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4379285907> ?p ?o ?g. }

• W4379285907 endingPage "101" @default.
• W4379285907 startingPage "101" @default.
• W4379285907 abstract "101 Background: Neoadjuvant ipilimumab (IPI) + nivolumab (NIVO) has been shown to induce high pathologic response rates associated with an excellent relapse-free survival (RFS) in high-risk stage III melanoma. While OpACIN-neo tested different neoadjuvant IPI + NIVO regimens followed by therapeutic lymph node dissection (TLND) without adjuvant systemic therapy (ST), PRADO tested a personalized approach. In patients (pts) achieving a major pathologic response (MPR; ≤10% viable tumor), TLND and adjuvant ST were omitted, and pts with pathologic non-response (pNR; >50% viable tumor) were treated with adjuvant ST (BRAFi/MEKi or anti-PD1) ± radiotherapy after TLND. Here, we address 1) whether omitting TLND in MPR pts had an adverse effect on long-term survival and 2) whether adding adjuvant ST in pNR pts had a favorable effect on survival. Methods: The 3-year (3y) RFS and distant metastasis-free survival (DMFS) of pts with MPR and pNR from PRADO and OpACIN-neo were analyzed, comparing MPR pts with TLND versus without TLND and pNR pts with adjuvant ST versus without adjuvant ST. Survival rates were calculated and compared with Kaplan-Meier and log-rank methods. Associations between baseline characteristics and RFS or DMFS were examined by Cox regression analysis. Results: Median follow-up was 37.9 months in PRADO (cutoff Jan 8, 2023) and 46.8 months in OpACIN-neo (cutoff Feb 14, 2022). For MPR pts, TLND omission did not affect survival, with a 3y RFS of 93% versus 96% (p=0.47) and 3y DMFS 98% versus 98% (p=0.92) for pts without TLND (n=59) versus with TLND (n=53), respectively. In pNR pts, an indication for a RFS and DMFS benefit was seen favoring pts with adjuvant ST (n=17: n=10 BRAFi/MEKi and n=7 anti-PD1) over pts without adjuvant ST (n=23), with 3y RFS rates being 64% versus 35% (p=0.10) and 3y DMFS rates 70% versus 52% (p=0.24). Baseline clinical characteristics did not differ between PRADO and OpACIN-neo pts or were not associated with RFS and DMFS. Conclusions: Omitting TLND in MPR pts after neoadjuvant IPI + NIVO seems not to affect RFS/DMFS. Given the high survival rates, adjuvant ST is unlikely to give further benefit in these pts. In pts with pNR, addition of adjuvant ST with ongoing anti-PD1 or switch to BRAFi/MEKi appears to improve RFS and DMFS. Clinical trial information: NCT02977052 . [Table: see text]" @default.
• W4379285907 created "2023-06-05" @default.
• W4379285907 creator A5000202300 @default.
• W4379285907 creator A5004800309 @default.
• W4379285907 creator A5007717740 @default.
• W4379285907 creator A5009376752 @default.
• W4379285907 creator A5013384569 @default.
• W4379285907 creator A5019573174 @default.
• W4379285907 creator A5022520811 @default.
• W4379285907 creator A5022668182 @default.
• W4379285907 creator A5031300611 @default.
• W4379285907 creator A5052393304 @default.
• W4379285907 creator A5052672458 @default.
• W4379285907 creator A5070576000 @default.
• W4379285907 creator A5072403971 @default.
• W4379285907 creator A5073219721 @default.
• W4379285907 creator A5081462567 @default.
• W4379285907 creator A5083026922 @default.
• W4379285907 creator A5084535555 @default.
• W4379285907 creator A5086670127 @default.
• W4379285907 creator A5087767413 @default.
• W4379285907 creator A5088390068 @default.
• W4379285907 date "2023-06-01" @default.
• W4379285907 modified "2023-10-18" @default.
• W4379285907 title "The impact of response-directed surgery and adjuvant therapy on long-term survival after neoadjuvant ipilimumab plus nivolumab in stage III melanoma: Three-year data of PRADO and OpACIN-neo." @default.
• W4379285907 doi "https://doi.org/10.1200/jco.2023.41.16_suppl.101" @default.
• W4379285907 hasPublicationYear "2023" @default.
• W4379285907 type Work @default.
• W4379285907 citedByCount "0" @default.
• W4379285907 crossrefType "journal-article" @default.
• W4379285907 hasAuthorship W4379285907A5000202300 @default.
• W4379285907 hasAuthorship W4379285907A5004800309 @default.
• W4379285907 hasAuthorship W4379285907A5007717740 @default.
• W4379285907 hasAuthorship W4379285907A5009376752 @default.
• W4379285907 hasAuthorship W4379285907A5013384569 @default.
• W4379285907 hasAuthorship W4379285907A5019573174 @default.
• W4379285907 hasAuthorship W4379285907A5022520811 @default.
• W4379285907 hasAuthorship W4379285907A5022668182 @default.
• W4379285907 hasAuthorship W4379285907A5031300611 @default.
• W4379285907 hasAuthorship W4379285907A5052393304 @default.
• W4379285907 hasAuthorship W4379285907A5052672458 @default.
• W4379285907 hasAuthorship W4379285907A5070576000 @default.
• W4379285907 hasAuthorship W4379285907A5072403971 @default.
• W4379285907 hasAuthorship W4379285907A5073219721 @default.
• W4379285907 hasAuthorship W4379285907A5081462567 @default.
• W4379285907 hasAuthorship W4379285907A5083026922 @default.
• W4379285907 hasAuthorship W4379285907A5084535555 @default.
• W4379285907 hasAuthorship W4379285907A5086670127 @default.
• W4379285907 hasAuthorship W4379285907A5087767413 @default.
• W4379285907 hasAuthorship W4379285907A5088390068 @default.
• W4379285907 hasConcept C10515644 @default.
• W4379285907 hasConcept C121608353 @default.
• W4379285907 hasConcept C126322002 @default.
• W4379285907 hasConcept C143998085 @default.
• W4379285907 hasConcept C146357865 @default.
• W4379285907 hasConcept C151730666 @default.
• W4379285907 hasConcept C2777658100 @default.
• W4379285907 hasConcept C2777701055 @default.
• W4379285907 hasConcept C2777863537 @default.
• W4379285907 hasConcept C2777982462 @default.
• W4379285907 hasConcept C2778292576 @default.
• W4379285907 hasConcept C2780030458 @default.
• W4379285907 hasConcept C2781433595 @default.
• W4379285907 hasConcept C502942594 @default.
• W4379285907 hasConcept C50382708 @default.
• W4379285907 hasConcept C530470458 @default.
• W4379285907 hasConcept C71924100 @default.
• W4379285907 hasConcept C86803240 @default.
• W4379285907 hasConceptScore W4379285907C10515644 @default.
• W4379285907 hasConceptScore W4379285907C121608353 @default.
• W4379285907 hasConceptScore W4379285907C126322002 @default.
• W4379285907 hasConceptScore W4379285907C143998085 @default.
• W4379285907 hasConceptScore W4379285907C146357865 @default.
• W4379285907 hasConceptScore W4379285907C151730666 @default.
• W4379285907 hasConceptScore W4379285907C2777658100 @default.
• W4379285907 hasConceptScore W4379285907C2777701055 @default.
• W4379285907 hasConceptScore W4379285907C2777863537 @default.
• W4379285907 hasConceptScore W4379285907C2777982462 @default.
• W4379285907 hasConceptScore W4379285907C2778292576 @default.
• W4379285907 hasConceptScore W4379285907C2780030458 @default.
• W4379285907 hasConceptScore W4379285907C2781433595 @default.
• W4379285907 hasConceptScore W4379285907C502942594 @default.
• W4379285907 hasConceptScore W4379285907C50382708 @default.
• W4379285907 hasConceptScore W4379285907C530470458 @default.
• W4379285907 hasConceptScore W4379285907C71924100 @default.
• W4379285907 hasConceptScore W4379285907C86803240 @default.
• W4379285907 hasIssue "16_suppl" @default.
• W4379285907 hasLocation W43792859071 @default.
• W4379285907 hasOpenAccess W4379285907 @default.
• W4379285907 hasPrimaryLocation W43792859071 @default.
• W4379285907 hasRelatedWork W2395564121 @default.
• W4379285907 hasRelatedWork W2618451551 @default.
• W4379285907 hasRelatedWork W2752227448 @default.
• W4379285907 hasRelatedWork W2780485172 @default.
• W4379285907 hasRelatedWork W3128878661 @default.
• W4379285907 hasRelatedWork W3157008565 @default.
• W4379285907 hasRelatedWork W3181948680 @default.
• W4379285907 hasRelatedWork W3200550458 @default.

• next